Profitable Specialty Pharmaceuticals Company Investment Opportunity in Bengaluru, India
Company with 170 pharma and R&D alliances that provides clinical trials and molecular innovations.
| Established | 5-10 year(s) |
| Employees | 10 - 50 |
| Legal Entity | Private Limited Company |
| Reported Sales | USD 350 thousand |
| Run Rate Sales | USD 700 thousand |
| EBITDA Margin | 40 % |
| Industries | Specialty Pharmaceuticals |
| Locations | Bengaluru |
| Local Time | 8:34 AM Asia / Kolkata |
| Listed By | Business Owner / Director |
| Status | Active |
Partial Stake Sale
USD
1.17 million
for
50.0%
stake
(Native Currency: INR 100,000,000)
Reason: We are seeking investment to expand our global footprint.
Includes physical assets worth
USD
117 thousand
Interested to connect with advisors
Name, Phone, Email
Available after connect
Business Name
Available after connect
User Verification
Documents
Business Overview
- We are a global speciality contract research organization (CRO) headquartered in India.
- Operate mainly in India, Europe, and the Middle East. We support our clients through pharma drug development and clinical trials.
- Our company directly covers more than 20 countries and all key markets in Asia-Pacific, Japan, Europe, N. America and South Korea.
- We are a quality leader in our industry and focus on the therapeutic areas of immunology, respiratory and allergy, endocrinology, oncology, GI, and CNS based on experience and expertise.
- We have 170 pharma and R&D companies who are our clients.
- Our customers are mainly from pharma, R&D, manufacturing, fertilizers, seeds, pesticides, and diagnostics.
- Company focuses on bringing hitherto unavailable novel medicines, drug-delivery devices, companion diagnostics, and diagnostic imaging agents to medical oncologists, surgical oncologists, radiation oncologists, interventional radiologists, and rheumatology. These include, but are not limited to, small molecules, recombinant proteins, monoclonal antibodies (mAbs), drug-delivery devices, and diagnostics in oncology and immunology.
- Due to Covid we saw an increase in the demand for our services. This is the reason for the high growth rate of our sales.
- Operate mainly in India, Europe, and the Middle East. We support our clients through pharma drug development and clinical trials.
- Our company directly covers more than 20 countries and all key markets in Asia-Pacific, Japan, Europe, N. America and South Korea.
- We are a quality leader in our industry and focus on the therapeutic areas of immunology, respiratory and allergy, endocrinology, oncology, GI, and CNS based on experience and expertise.
- We have 170 pharma and R&D companies who are our clients.
- Our customers are mainly from pharma, R&D, manufacturing, fertilizers, seeds, pesticides, and diagnostics.
- Company focuses on bringing hitherto unavailable novel medicines, drug-delivery devices, companion diagnostics, and diagnostic imaging agents to medical oncologists, surgical oncologists, radiation oncologists, interventional radiologists, and rheumatology. These include, but are not limited to, small molecules, recombinant proteins, monoclonal antibodies (mAbs), drug-delivery devices, and diagnostics in oncology and immunology.
- Due to Covid we saw an increase in the demand for our services. This is the reason for the high growth rate of our sales.
Products & Services Overview
Our business model encompasses global access / early access programs, named patient programs, and securing product registrations for exclusive commercial distribution in South Asia.
Assets Overview
Physical assets include research and development machinery and a fully equipped research lab in Mysore.Intangible assets include intellectual approvals and patents.
Facilities Overview
We have rented offices in Bangalore of area 1,200 sq feet, a lab in Mysore of area 2,500 sq feet, and an office in the Netherlands of area 1,200 sq feet.
Capitalization Overview
Not Disclosed
Recent Activity
-
Earlier than 15 daysDirector, Pharmaceuticals Manufacturing And Distribution, Welwyn Garden City, Individual Investor / Buyer connected with the Business
-
Earlier than 15 daysFounder And CEO, IT, Bengaluru, Corporate Investor / Buyer connected with the Business
-
Earlier than 15 daysOwner, Tobacco, Bengaluru, Individual Investor / Buyer connected with the Business
Tags:
Specialty Pharmaceuticals Company Investment Opportunity in Bangalore, India
·Specialty Pharmaceuticals Company Investment Opportunity in Bengaluru
·Invest in Specialty Pharmaceuticals Company in Bangalore, India
·Specialty Pharmaceuticals Company Investment Opportunity
·Invest in Specialty Pharmaceuticals Company in Bengaluru
·Invest in Specialty Pharmaceuticals Company
·Investment Opportunity in Bangalore, India
·Investment Opportunity in Bengaluru
·Invest in Bangalore, India
·Invest in Bengaluru
Disclaimer: SMERGERS is a regulated marketplace for connecting business sell sides with investors, buyers, lenders and advisors. Neither SMERGERS represents nor guarantees that the information mentioned above is complete or correct. Note that SMERGERS is not liable for any loss, damage, costs, claims and expenses whatsoever arising from transacting with any other user from the website. The final responsibility of conducting a thorough due diligence and taking the transaction forward lies with the users. Please read best practices on SMERGERS.
Contact Business
11 Investors already contacted this Business.
Register below to connect now!
- Social
- Register
- Login
Who uses SMERGERS?
... and 124,000+ other businesses of all sizes.
Disclaimer: SMERGERS is a regulated marketplace for connecting business sell sides with investors, buyers, lenders and advisors. Neither SMERGERS represents nor guarantees that the information mentioned above is complete or correct.
You might also be interested in these businesses